Different Mycobacterium spp. infections may indicate varied treatment regimens in the clinic. Thus, the species-level identification of Mycobacterium spp. is one of the most important tasks for a clinical microbiology laboratory. Although matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has emerged as a rapid and accurate method for the identification of mycobacteria, this method lacks a comprehensive evaluation of the identification accuracy for clinically collected mycobacteria using VITEK MS Knowledge Base Version 3.0 (Ver 3.0). The objectives of the present study were to evaluate the identification performance of Mycobacterium spp. using Ver 3.0 and a sample processing kit for strain inactivation and protein extraction. Among the 507 Mycobacterium isolates, 46 isolates were M. tuberculosis, and 461 isolates were nontuberculous mycobacteria (NTM) (including 27 species: 17 species were slowly growing mycobacteria (SGM), and 10 species were rapidly growing mycobacteria (RGM)). The VITEK MS V3.0 library was used to correctly identify 476/507 (93.9%) isolates (425 isolates were correctly identified initially, and 51 more isolates were correctly identified on repeat), 23/507 (4.5%) isolates were unidentified, and 8/507 (1.6%) isolates were misidentified. In summary, we showed that Mycobacterium spp. can be adequately identified by Ver 3.0 in combination with the use of a standard sample processing kit.
Introduction
Mycobacterium spp. comprise a large group of microorganisms, and many species within the genus are prominent pathogens, particularly the M. tuberculosis complex (MTBC) 1 . Tuberculosis (TB) caused by MTBC is the ninth leading cause of death worldwide and the leading cause from a single infectious agent, ranking above HIV/AIDS, with 10.4 million illnesses and 1.8 million deaths reviewed in the 2016 WHO report 2 . Apart from MTBC, many NTM (nontuberculous mycobacteria) species are also sources of important diseases in humans 3, 4 . These species are considered important opportunistic pathogens that can cause pulmonary, skin, soft tissue, and disseminated infections [5] [6] [7] .
The identification of Mycobacterium at the species level is not only important to discriminate true pathogens from environmental contaminants but also to reveal differences in clinical relevance and treatment regimens between NTM species 8, 9 . Traditionally, Mycobacterium spp. have been identified using phenotypic methods 10 . However, these methods are laborious and cumbersome and may require long incubation periods. These procedures cannot meet the demands of clinical requirements that require prompt and accurate identification results. Thus, rapid, accurate identification of Mycobacterium is an important task of the clinical mycobacteriology laboratory 9 . The use of molecular techniques has dramatically accelerated the Mycobacterium diagnostic process. DNA probes and PCR-based detection have been available for many years and show good performance for certain species but show cross-reactions with M. intracellulare and M. fortuitum species, along with the M. avium complex [11] [12] [13] [14] [15] . Currently, the most reliable methods for the identification of all Mycobacterium spp. involve the molecular analysis of selected genes, such as 16 S rRNA, rpoB, and hsp65 16 . However, these techniques are expensive, technically complex, time-consuming, require specific equipment and expertise and have limited availability.
Matrix-assisted laser desorption ionization-time of flight mass spectrometry (MALDI-TOF MS) has revolutionized the identification of microorganisms and has recently been applied for the identification of Mycobacterium spp 17, 18 . Many reports adopt this technology for the identification of Mycobacterium spp., but the results have been greatly varied [18] [19] [20] [21] [22] [23] [24] [25] . Due to the presence of mycolic acids and the pathogenicity of mycobacteria, reliable inactivation and reproducible sample extraction protocols present great challenges, which might partly explain the great variances in the findings among researchers 17, 26, 27 . Another explanation may be the coverage of Mycobacterium spp. included in different commercial database platforms 19, 22, 28, 29 .
The objective of the present study was to evaluate the identification performance of clinical Mycobacterium spp. using the VITEK MS Knowledge Base Version 3.0 in combination with the VITEK ® MS Mycobacterium/ Nocardia Kit (bioMérieux SA, Marcy L'Étoile, France) to generate highly reliable results in sample processing.
Results

Inactivation results
To ensure the complete inactivation of Mycobacterium, we tested 10 isolates, including four MTBC and six NTM isolates. As expected, these pathogens were nonviable after a 10-min incubation in 70% ethanol following selection with a 1-µL inoculation loop after inactivation. Neither the MGIT nor the LJ medium made any difference in viability for any of the isolates tested after 6 weeks of incubation. 
VITEK MS identification
Unidentified and misidentified Isolates by VITEK MS
A total of 23 isolates were unidentified by the VITEK MS Ver 3.0 system. Among these species, the 11 isolates not in the database included 1 M. florentinum, 6 M. marseillense, 2 M. colombiense, and 2 M. monacense. The other 12 unidentified isolates included 1 MTBC, 3 M. intracellulare, and 2 each of M. avium, M. kansasii, M. abscessus, and M. fortuitum isolates. There were no misidentifications at the genus level when using the VITEK MS Ver 3.0 database. At the species level, 8 isolates were misidentified. Misidentifications were observed for 4 isolates of M. gastri, which were identified as M. kansasii, 2 M. parascrofulaceum isolates were identified as M. scrofulaceum and 1 isolate each of M. timonense and M. chimaera was identified as M. intracellulare. For other species, one M. scrofulaceum isolate was identified with a 50% confidence value for both M. scrofulaceum and M. intracellulare. The results are shown in Table 2 .
Discussion
To our knowledge, this study represents the most comprehensive evaluation of the CE/IVD and FDAapproved VITEK MS V3.0 for the identification of clinically isolated mycobacteria. The correct identification rate of Mycobacterium spp. after retesting was 93.9%. In addition, no isolates were misidentified at the genus level through VITEK MS V3.0.
MALDI-TOF MS is widely used for routine bacterial identification in clinical laboratories. Unlike bacteria and yeasts, mycobacteria have thicker cell walls and thus These species were all identified as M. fortuitum group f These subspecies were all identified as M. abscessus in VITEK MS V3.0 database require an additional protein extraction procedure to ensure effective identification. Although many methods have been described, and perfect inactivation effects were obtained 18, 21 , there is still a lack of uniform procedures for strain inactivation and protein extraction. Here, we used a kit from bioMérieux for these purposes.
MTBC remains the most important group within the genus Mycobacterium from a global and clinical perspective 2 . In the present study, 1/46 (2.2%) isolates were unidentified using the VITEK MS V3.0 analysis. This excellent identification performance with MTBC indicated that MALDI-TOF MS could be used as a powerful clinical tool. For SGM, the most frequently involved pathogens in human diseases were Mycobacterium intracellulare and Mycobacterium avium 30 . In the present study, only 2/56 (3.6%) M. avium and 3/153 (2%) M. intracellulare were unidentified; these rates are lower than the previously reported rates between 7.7 and 27.8% 17, 31 . Mycobacterium colombiense, M. chimaera, M. marseillense and M. timonense are members of species closely related to M. avium and M. intracellulare but absent from the VITEK MS V3.0 database 32, 33 . During the VITEK MS V3.0 analysis, all M. colombiense and M. marseillense strains were not identified, but M. chimaera and M. timonense were misidentified as M. intracellulare. This misidentification may be due to the close phylogenetic relationships between M. intracellulare and these two species 34, 35 . Mycobacterium kansasii is second in frequency to M. avium and M. intracellulare as a cause of NTM lung disease, and its response to chemotherapy is much better 5 . Although the present results showed that the identification performance of M. kansasii is excellent, the major problem is that M. gastri was readily misidentified as M. kansasi. One reason for this misidentification is that incubation conditions may lead to excessive polymer production, which could greatly interfere with the spectra acquisition during MALDI-TOF MS analysis, while other explanations may be attributed to the genetic similarity between M. kansasii and M. gastri, as well as the potential that the entire range of strain diversity is not covered in the databases. However, these two species were also easy to interchange and may still need more spectra incorporated in the database 22, 29, [36] [37] [38] . Other SGM species involved in pulmonary diseases were Mycobacterium gordonae, an SGM species that rarely causes human diseases, is a frequent clinical isolate, and all of these isolates were correctly identified 40 . Other SGM species mainly isolated from the respiratory tract but rarely associated with human diseases, such as M. parascrofulaceum, M. celatum, and M. arupense, were also included in the present study [41] [42] [43] . These findings were also subjected to the close relationships and limited spectra included in the knowledge database; one isolate of M. scrofulaceum was not well identified, while two isolates of M. parascrofulaceum were misidentified as M. scrofulaceum 44 . For the limited numbers of some species, such as M. celatum and M. arupense, 100% correct identifications were also observed. In addition to human disease-related SGM species, these rare SGM species also showed good identification performance in VITEK MS V3.0. Evaluation of more strains of these rare species could provide useful information.
The RGM are opportunistic pathogens that produce disease in a variety of clinical settings 39 . The three major clinically important species of RGM, M. abscessus, M. fortuitum group and M. chelonae, are responsible for approximately 80% of RGM-related mycobacterial diseases 7 . The M. abscessus complex, consisting of three subspecies (M. massiliense, M. bolletii, and M. abscessus), is the most common of the RGM species that cause NTM pulmonary diseases. Among these species, M. abscessus subsp abscessus is the dominating subspecies and is responsible for treatment failures, mainly due to the inducible resistance of an erm (position 28: C to T) mutation, which results in clarithromycin resistance, which would be impossible in M. abscessus subsp massiliense due to its incomplete erm gene 45, 46 ; thus, different subspecies of M. abscessus infections may result in varied therapies 47 . However, although the correct identification rate was perfect for M. abscessus (the unidentified two isolates are smooth-growing, one each of M. abscessus subspecies abscessus and massiliense), these subspecies could not be discriminated in the VITEK MS V3.0 knowledge database. In prospect, these subspecies should be differentiated by the VITEK MS IVD (In Vitro Diagnosis) system, owing to the different treatment requirements. M. fortuitum group includes up to 13 species, but the VITEK MS V3.0 knowledge database includes the seven most prominent and closely related species. Species such as M. peregrinum, M. senegalense and M. septicum, were all identified as the M. fortuitum group. Except for M. septicum species, M. peregrinum and M. senegalense were included in the database, which may be partially explained by the limited strains and spectra used for the database construction 48 . All M. chelonae isolates were correctly identified and well discriminated from the M. abscessus complex. As we only tested a limited number of M. chelonae isolates, more strains will be necessary for further confirmation. Other rarely isolated species, such as M. mucogenicum, M. mageritense, and M. vaccae, were well identified using VITEK MS V3.0. However, the limited number of isolates used in the present study was not enough to sufficiently evaluate the performance of these species using MALDI-TOF MS.
The present study was associated with a number of limitations. First, despite the large number of clinical Mycobacterium isolates included in the present study, almost all isolates were from respiratory tract samples, and a limited number of species were recovered. Second, only a few isolates were tested for some species, and a more thorough evaluation would seem worthwhile with more isolates collected globally. Third, we did not examine the identification performances of Mycobacterium species from other liquid media and thus cannot draw any conclusions regarding the performance of other isolation media. In follow-up studies, we plan to identify Mycobacterium directly from positive MGIT broth cultures to obtain a more comprehensive evaluation of MALDI-TOF MS used for Mycobacterium identification.
Nevertheless, the present study had several strengths. First, the present study evaluated the performance of the identification of a large number of clinical Mycobacterium isolates using the CE/IVD and FDA-approved VITEK MS Version 3.0 database. Second, the combined use of the VITEK MS Mycobacterium/Nocardia sample processing kit in Mycobacterium inactivation and protein extraction generated sample spectra compatible with the reference spectra provided by the manufacturer. With the process presented here, the identification performance was slightly higher than those reported by other researchers using the VITEK MS Version 3.0 database 28, 29 . In summary, we showed that Mycobacterium spp. can be adequately identified by the VITEK MS Version 3.0 database. The use of a commercial sample processing kit and standard protocols are likely to yield highly reliable results in the identification of Mycobacterium species. This study further confirmed that the implementation of MALDI-TOF MS in the clinical laboratory enables the highly accurate identification of Mycobacterium species.
Materials and methods
Clinical isolates
A total of 507 Mycobacterium isolates representing 28 species, were enrolled in the present study. Clinical samples were submitted to the Shanghai Pulmonary Hospital for mycobacterial culture, and these isolates were recovered between June 2015 and March 2017. For MALDI-TOF MS analysis, all isolates were subcultured on Löwenstein-Jensen (LJ) medium at 35°C. Rapidly growing species were tested after 3 to 10 d of incubation, while slowly growing species were tested after 3 to 5 weeks of incubation at 35°C.
Viability assay
Inactivation was performed as previously described 17, 21, 31 . Briefly, colonies were selected from LJ medium with a 1-µL loopful of the organisms and then suspended in 1 mL of 75% ethanol and vortexed at maximum speed on a vortex adapter (Vortex-Genie 2, Scientific Industries, Inc. Bohemia, NY, USA) for 15 min followed by incubation for another 10 min at room temperature for inactivation. After centrifugation, the pellet was resuspended in 200 µL of sterile water, and the supernatant was discarded. Viability was measured by inoculating samples (100 µL) in BACTEC MGIT 960 bottles (BD Diagnostics, Shanghai, China) and subsequently assessing for growth on LJ medium. The LJ medium was examined daily for growth during the first week and then weekly thereafter, for a total of 6 weeks under incubation 28 . Viability was tested using the following strains: four isolates of M. tuberculosis and six NTM isolates (one each of M. abscessus, M. fortuitum, M. kansasii, M. intracellulare, M. avium and M. lentiflavum).
VITEK
® MS Mycobacterium/Nocardia Kit All procedures were performed with the VITEK® MS Mycobacterium/Nocardia Kit (bioMérieux SA, Marcy L'Étoile, France). In brief, a 1-µL loopful of organisms was picked and transferred into a tube with glass beads and 70% ethanol, followed by vortexing for 15 min and incubation at room temperature for another 10 min. After the subsequent transfer and centrifugation, the dried pellets were uniformly dispersed with 70% formic acid and acetonitrile in turn. After centrifugation, 1 µL of the supernatant was transferred to the target slide. Once the sample was dry, 1 µL of CHCA matrix (bioMérieux SA, Marcy L'Eoile, France) was applied and allowed to dry prior to analysis. All slides were run within 3 h after preparation, and the identifications were run in automatic mode. For each isolate, a single extraction was performed and spotted in duplicate. For any isolates where discrepancies were observed, the isolate was confirmed by gene sequencing (16 S rRNA, hsp65 PRA or erm). For each run, Escherichia coli (ATCC 8739; American Type Culture Collection, Manassas, VA, USA) was used for calibration and quality control according to the manufacturer's protocols. Mycobacterium abscessus ATCC 19977 was used as a positive control, while negative controls were simultaneously analyzed, which was performed with spotted matrix only 49 .
VITEK MS knowledge base version 3.0 and MALDI-TOF MS analysis
Isolates were tested using the VITEK MS system (bioMérieux SA, Marcy L'Eoile, France), and the results were analyzed using knowledge base (KB) Version 3.0. Version 3.0 KB includes 49 Mycobacterium species grouped into 39 taxa, 14 Nocardia species, 48 mold species grouped into 47 taxa and 197 other new bacteria and yeasts, most of which are clinically relevant. Among the added 49 Mycobacterium species, there are 45 NTM (including 23 SGM and 22 RGM) and 4 MTBC species 29 . During the present analysis, if the identification score was lower than 99%, then reanalysis was performed, or the extraction was repeated. Repeat testing was performed with the original culture or a newly sub-cultured isolate, according to the procedures specified above. If an isolate still yielded no identification, then this sample was considered as an unidentified result 36 . For results in which the confidence score was lower than 50%, repeated extraction analysis and sequencing were performed.
Sequencing
All analyzed strains were sequenced across the full 16 S rRNA gene using the universal primers 27-FOR (AGAGTTTGATCMTGGCTCAG) and 1492-REV (TACGGYTACCTTGTTACGACTT). For species such as M. kansasii and M. gastri, M. fortuitum group, M. peregrinum and M. septicum, hsp65 PRA genes (FOR: ACCAACGATGGTGTGTCCAT and REV: CTTGTCGAACCGCATACCCT) were used to supplement the identification 50, 51 . The erm gene was used for differentiating between Mycobacterium abscessus subspecies abscessus, bolletii and massiliense 45 . If the isolate identification obtained by VITEKVITEK MS Knowledge Base Version 3.0 was consistent with the gene sequence, then the result was considered as correct. For discrepancies between sequencing and MALDI-TOF MS analysis, the sequencing result was considered the gold standard.
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